Jorge
Showing 1–2 of 2 transcripts.
- a16z1h 1m
The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Elliot Hershberg, Lada Nuzhna, Jorge, Erik
Industry leaders analyze a critical bottleneck in biotech where rising R&D costs, regulatory stringency, and a lack of U.S. first-in-human trials have created an environment where innovation is stifled by China's accelerated approval models. While AI is projected to reshape drug discovery by targeting previously undruggable molecules and solving efficacy failures, experts warn that current applications remain misaligned with the primary cost drivers of clinical development. The future of the sector depends on shifting from single-molecule breakthroughs to multi-modal platforms that address aging and leverage new technologies to restore the "invention" advantage against global competitors.
- a16z27 min
Biotech CEO on where we are in the fight to cure cancer
Former Halozyme CEO Jonathan Lim leverages his experience scaling biotech startups to lead Araska Therapeutics, a company targeting the historically undruggable RAS pathway with a pipeline including the pan-RAF inhibitor Naporafenib. Concurrently, his family office, City Hill Ventures, manages a diversified portfolio of life sciences assets and media projects that parallel the high-risk, high-reward dynamics of pharmaceutical development. Lim's strategy emphasizes capital preservation and the combination of novel molecular glues with standard therapies to drive long-term remission rates beyond current limits in pancreatic, lung, and colon cancers.